Zobrazeno 1 - 9
of 9
pro vyhledávání: '"J. P. Van Der Post"'
Autor:
R.H. de Rijk, J. P. Van Der Post, Gabriel E. Jacobs, Rik C. Schoemaker, J. van Pelt, Dhm Hoeberechts-Lefrandt, Ljca Smarius, ML de Kam, Jma van Gerven, Harm J. Gijsman, Frans G. Zitman
Publikováno v:
Journal of Psychopharmacology. 22:426-433
5-hydroxytryptophan (5-HTP) is a direct 5-hydroxytryptamine (5-HT) precursor used to assess central serotonergic function. Its use has been limited by a narrow window between neuroendocrine changes and side effects, and variable kinetics related to i
Autor:
S. J. De Visser, J.M.A. van Gerven, E. Bortey, M. Woelfler, J. Vornov, E. S. Burak, ML de Kam, B. S. Slusher, Adam F. Cohen, T. Limsakun, D. C. Hilt, J. P. Van Der Post
Publikováno v:
British Journal of Clinical Pharmacology. 60:128-136
The aim was to assess the central nervous system (CNS) effects, pharmacokinetics and safety of GPI 5693, an inhibitor of a novel CNS-drug target, NAALADase which is being evaluated for the treatment of neuropathic pain.This was a double-blind, placeb
Publikováno v:
Journal of Psychopharmacology. 18:109-114
This study aimed to evaluate eye blinking as a marker for central dopaminergic activity by investigating the effects of sulpiride (D2-antagonist) and lisuride (D2-agonist) on spontaneous eye blinks. Twelve healthy subjects were included in a randomiz
Autor:
Adam F. Cohen, J. P. Van Der Post, J.M.A. van Gerven, P. P. de Waal, F. Cornet, S. J. De Visser
Publikováno v:
British Journal of Clinical Pharmacology. 55:39-50
Studies of novel centrally acting drugs in healthy volunteers are traditionally concerned with kinetics and tolerability, but useful information may also be obtained from biomarkers of clinical endpoints. A useful biomarker should meet the following
Publikováno v:
British Journal of Clinical Pharmacology. 51:119-132
Studies of novel antipsychotics in healthy volunteers are traditionally concerned with kinetics and tolerability, but useful information may also be obtained from biomarkers of clinical endpoints. A useful biomarker should meet the following requirem
Autor:
L. Xue, Adam F. Cohen, L.K. Vessey, Rik C. Schoemaker, M De Smet, SL de Haas, S. J. De Visser, J.M.A. van Gerven, K Van Dyck, M.G. Murphy, R. Ramakrishnan, J. P. Van Der Post
Publikováno v:
Journal of psychopharmacology (Oxford, England). 22(1)
The use of non-selective γ-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered by unfavourable side effects. some of these may be associated with binding properties to ce
Publikováno v:
Journal of psychopharmacology (Oxford, England). 18(2)
Previous single-dose studies have shown clear blood pressure-lowering effects of a potential sustained release (SR) profile of rilmenidine, with concentration-dependent effects on the central nervous system. The aim of this study was to evaluate pote
Autor:
ML de Kam, J. P. Van Der Post, J. M. A. van Gerven, Adam F. Cohen, L. A. W. Noordzij, G. J. Blauw
Publikováno v:
Journal of psychopharmacology (Oxford, England). 16(4)
The sensitivity of several neurophysiological and cognitive tests to different levels of hypoxia was investigated. Cerebral hypoxia in healthy volunteers may be a disease model for dementia or other forms of brain dysfunction. Twelve healthy subjects
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.